Member Profile

Maria Von Med-Biotechnology Co., Ltd. is an emerging biopharmaceutical company established in Taiwan in 2008. Since its establishment, Maria Von has worked to develop cell-based therapeutics aiming to serve the world market. Using human cells and tissues, our adopted regenerative medicine approach aims to restore and regenerate damaged cells and tissues to their original states. The company is dedicated to the research, development and commercialization of innovative treatments for unmet medical needs and age-related degeneration; as well as to generate substantial value for our shareholders while complying with legal statutes and ethical guidelines.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2008 Maria Von set up GTP lab in 2008 and was certified by TFDA in 2011 and 2015.
   2010 Maria Von R&D project in 2010 was sponsored by Small & Medium Enterprise Administration, Ministry of Economic Affairs , Taiwan ( R.O.C)
   2011 Maria Von was granted allowance of Phase I study of autologous transplantation of cultured fibroblasts for wound, depressed scars and other pathological skin defects filling and replacement in 2011.
   2015 Maria Von was granted a Good Manufacturing Practice Certificate for Maria Von PRP kit by TFDA in 2015.
   2015 Maria Von PRP kit was developed in 2013 and was issued for Medical Device License by TFDA in 2015.
   2015 Maria Von worked together with Fujifilm Group company Japan Tissue Engineering rescued victims of Taiwan water park explosion by cell therapy in 2015.
   2016 Maria Von Human organ bank was certified by TFDA in 2016.
   2019 Maria Von worked together with hospitals and clinics are applying for a license for cell therapy from TFDA.